Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
November 29 2023 - 6:23AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2023
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
November 29, 2023
2
Exhibit 99.1
Results of Annual General
Meeting
MELBOURNE, AUSTRALIA AND SAN
FRANCISCO, USA - 29 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”)
advises that all resolutions considered at the Annual General Meeting held today were carried by poll.
In accordance with ASX Listing
rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution
are attached.
Phillip Hains
Company Secretary
Alterity Therapeutics Limited
ACN 080 699 065
Level 3, 62 Lygon Street Carlton Victoria 3053 Australia
www.alteritytherapeutics.com
The following information is provided in accordance with
section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution details |
Instructions given
to validly appointed proxies
(as at proxy close) |
Number of votes cast
on the poll
(where applicable)
|
Resolution
Result
|
Resolution |
Resolution
Type |
For |
Against |
Proxy’s
Discretion |
Abstain |
For |
Against |
Abstain* |
Carried /
Not Carried |
1 Non-binding resolution to adopt Remuneration Report |
Ordinary |
80,616,129
76.83% |
21,954,866
20.92% |
2,360,040
2.25% |
14,602,600 |
89,426,169
80.29% |
21,954,866
19.71% |
14,602,600 |
Carried |
2 Re-Election of Director Mr. Peter Marks |
Ordinary |
106,311,290
85.25% |
16,351,485
13.11% |
2,043,660
1.64% |
12,043,800 |
118,077,176
87.84% |
16,351,485
12.16% |
12,043,800 |
Carried |
3 Re-Election of Director Mr. Lawrence Gozlan |
Ordinary |
106,475,730
85.62% |
15,842,045
12.74% |
2,043,660
1.64% |
12,022,800 |
118,241,616
88.18% |
15,842,045
11.82% |
12,022,800 |
Carried |
4 Ratification of prior issue of shares (Placement March 2023) |
Ordinary |
115,193,651
85.81% |
17,027,399
12.68% |
2,033,660
1.51% |
3,043,925 |
126,949,537
88.17% |
17,027,399
11.83% |
3,043,925 |
Carried |
5 Approval of 10% Placement Facility |
Special |
111,296,889
83.43% |
19,861,399
14.89% |
2,243,660
1.68% |
3,896,687 |
123,262,775
86.12% |
19,861,399
13.88% |
3,896,687 |
Carried |
| * | Votes cast by a person who abstains on an item are not counted
in calculating the required majority on a poll. |
Alterity Therapeutics (PK) (USOTC:PRNAF)
Historical Stock Chart
From May 2024 to Jun 2024
Alterity Therapeutics (PK) (USOTC:PRNAF)
Historical Stock Chart
From Jun 2023 to Jun 2024